{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016809","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.157328+00:00","generated_at":"2026-05-21T07:37:17.311009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M","bullets":["Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).","Operating income $0.7M vs $0.4M; nine-month operating income $1.4M vs loss $0.2M.","Net income $0.02 EPS vs $0.01; nine-month net income $1.0M ($0.03 EPS) vs loss $0.2M.","Two largest customers in contract manufacturing represented 83% of total revenue in nine-month period.","Co-CEOs cite customer base expansion and revenue growth from core business."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016809","json":"https://secwatch.observer/filing/0001437749-25-016809.json","markdown":"https://secwatch.observer/filing/0001437749-25-016809.md","text":"https://secwatch.observer/filing/0001437749-25-016809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/0001437749-25-016809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/inbp20250417_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T07:37:17.311009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}